ExpressionEdits
expressionedits.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$13M
1 round on record
Latest round
$13M
Seed · May 2024 · 2 yr ago
Backers
2
BlueYard Capital, Redalpine
The money's age
Long since its last round
28 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 12, 2025
Partnership ExpressionEdits Collaborates with Boehringer Ingelheim to Develop Enhanced Gene Therapies · FinanzNachrichten.de
May 28, 2024
Raised a round Seed $13M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | May 2024 | $13M | — | businesswire.com |
Registers and programsofficial lists and records that name the company
| Legal entity | ExpressionEdits Ltd | its site |
Founders and leadersfrom filings, registers and the company's site
Oliver Sims InvestorDirectorcompany's site
Backed byfrom the funds' portfolios and accelerator catalogs
BlueYard Capital 
Redalpine Similar startupsby what they do, their industry and backers
Protein Splicing to Develop the Next Generation of Genetic Medicines.
About Us We build the medicines we wish existed CPTx is a genetic medicines company redefining how we treat disease using immune-silent…
We’re building 10× better chip-cooling to unlock the next 100× better computer.
Instant Quantification of genetic modifications for Cell and Gene Therapies.
Apoha's Liquid State intelligence unlocks the next fundamental data class of molecular science to design better medicines, food, and…
The world's first searchable ecosystem of linked genetic and medical data. Get paid to share your health and genetic data with researchers.
Overview
Getting genetic syntax right.. With precise use of genetic grammar in transgenic design, ExpressionEdits unlocks the capacity to make proteins previously beyond reach.
News
ExpressionEdits Collaborates with Boehringer Ingelheim to Develop Enhanced Gene Therapies
Boehringer Ingelheim and ExpressionEdits will collaborate on the optimization of the expression of gene therapies ExpressionEdits announced a collaboration and licensing agreement with Boehringer
Read more
Report
ExpressionEdits Raises $13M in Seed Funding to Advance Protein Expression Using AI-Driven Intronization Technology
Read more
Report
People
Oliver Sims Investor
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Financials
Total raised
$13M
Latest round
Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Seed | 2024 | $13M | Details |